PURPOSE: To determine the influence of @entity1104 ( @entity3257 ) on treatment outcomes in @entity1 with neovascular age-related @entity1020 who were treated with anti- @entity7 agents using a treat and extend treatment regimen. METHODS: A retrospective consecutive case series of 204 eyes from 181 @entity1 with a minimum of 1 year of follow-up at Wills Eye Hospital Retina Service. Vitreomacular interface characteristics were determined by spectral domain optical coherence tomography. One hundred and fifty-three eyes (75%) had no signs of @entity3257 ( @entity3257 ), and 51 (25%) had @entity3257 . RESULTS: Baseline mean visual acuity was 20/133 with a mean central retinal thickness of 350.5  m in the @entity3257 group and was 20/145 with 371.8  m in the @entity3257 group. Mean visual acuity in the @entity3257 group was 20/83 and 20/64 at Years 1 and 2, respectively (P < 0.01 to baseline). Mean visual acuity in the @entity3257 group was 20/81 and 20/85 at Years 1 and 2, respectively (P < 0.01 to baseline). The central retinal thickness was 289.71  m and 267  m at Years 1 and 2, respectively (P < 0.01 to baseline) in the @entity3257 group and was 305.3  m and 289.24  m (P < 0.01 to baseline) in the @entity3257 group. The mean total number of injections at Year 1 for @entity3257 was 7.4 compared with 8.4 in @entity3257 (P = 0.001) and 5.5 versus 6.7 for the 2 groups in Year 2 (P = 0.027). The mean longest extension at Year 1 was 11.8 weeks compared with 10.1 week (P = 0.005) and for Year 2 was 14.1 weeks compared with 12 weeks (P = 0.041). CONCLUSION: The vitreomacular interface seems to have a significant influence on anti- @entity7 treatment intervals but not visual acuity or exudative control outcomes. Eyes with @entity3257 on spectral domain optical coherence tomography at baseline may require more intensive treatment with decreased ability to extend treatment intervals.

INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI- XXXX THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX).

@entity1 :: ('9606', 'Species') :: ['patients'] @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor'] @entity1104 :: ('MESH:D000267', 'Disease') :: ['vitreomacular adhesion'] @entity3257 :: ('MESH:C580335', 'Disease') :: ['VMA', 'non-VMA'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['macular degeneration']
@entity7 :: (7422,Gene) :: ['VASCULAR ENDOTHELIAL GROWTH FACTOR']
